PCM
RPRX icon

Penserra Capital Management’s Royalty Pharma RPRX Stock Holding History

Penserra Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-18
Closed – – 1181
2024
Q3 		$0 Sell
18
-9
-33% -$249 ﹤0.01% 1284
2024
Q2 		$1K Hold
27
– – ﹤0.01% 1238
2024
Q1 		$0 Hold
27
– – ﹤0.01% 1391
2023
Q4 		$0 Hold
27
– – ﹤0.01% 1343
2023
Q3 		$0 Buy
27
+21
+350% +$624 ﹤0.01% 1351
2023
Q2 		$0 Sell
6
-18
-75% -$610 ﹤0.01% 1313
2023
Q1 		$0 Hold
24
– – ﹤0.01% 1206
2022
Q4 		$0 Buy
+24
New +$1K ﹤0.01% 1216

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Penserra Capital Management's RPRX Position: Q4 2024 in Review

Penserra Capital Management sold out of Royalty Pharma (RPRX) in Q4 2024, closing a stake of 18 shares.

Penserra Capital Management first reported a position in RPRX in Q4 2022 and held it in 8 quarters. The position peaked at $1K in Q2 2024. 417 funds tracked by Wall St. Rank hold RPRX as of Q4 2024.

  • Penserra Capital Management reported no remaining Royalty Pharma position as of Q4 2024 after selling out during the quarter.
  • Penserra Capital Management sold 18 Royalty Pharma shares in Q4 2024.
  • Penserra Capital Management first reported a position in Royalty Pharma in Q4 2022 and held it in 8 quarters.
  • Penserra Capital Management's Royalty Pharma position peaked at $1K in Q2 2024.
  • 417 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2024.

Based on Penserra Capital Management's 13F filing for Q4 2024, filed 13 Feb 2025.